United Therapeutics Reaches Definitive Agreement to Acquire Miromatrix Medical

Published on: 

Merger expected to expand company’s existing complementary platform of organ manufacturing programs.

United Therapeutics announced in a company press release that it has agreed to terms to acquire Miromatrix Medical. Reportedly, the acquisition is expected to expand United Therapeutics’ existing complementary platform of organ manufacturing programs, which include ex-vivo lung perfusion, xenotransplantation, 3D bioprinting, and regenerative medicine approaches with the objective of creating an unlimited supply of tolerable, transplantable organs.


Under terms of the agreement, United Therapeutics will commence a tender offer to acquire all outstanding shares of Miromatrix for a purchase price of approximately $91 million and an additional $1.75 per share in cash upon the achievement of a clinical development milestone related to Miromatrix’s development-stage, fully implantable manufactured kidney product known as mirokidney by Dec. 31, 2025.

“At United Therapeutics, we are determined to rectify the severe shortage of transplantable organs,” said Martine Rothblatt, PhD, chairperson, CEO, United Therapeutics. “We expect that Miromatrix will help us in this mission, bringing a number of new approaches, highly skilled personnel, and state of the art facilities as additional shots on goal to complement our existing organ manufacturing programs.”

Reference: United Therapeutics to Acquire Miromatrix Medical. United Therapeutics. October 30, 2023. Accessed October 30, 2023. https://ir.unither.com/news/press-releases/press-release-details/2023/United-Therapeutics-to-Acquire-Miromatrix-Medical/default.aspx